Genmab — Juli 2019
-
So to your question on the duration. As we move into earlier lines, the duration of the treatment increases. When it comes to the subcu that we filed earlier this week, we think this is a very important opportunity for DARZALEX overall. Keep in mind that we're going to be able to reduce the infusion time from 8 hours that we have today to 5 minutes.
-
So that's going to give significant advantages in terms of adoption of DARZALEX, in particular in earlier lines and particularly when you think that 50% of the use of DARZALEX today in the U.S. is in oncology clinics in outpatient patients. So we think that this combination is going to make DARZALEX easier to use for physicians,
-
more convenient to patients, that if you add to that the number of studies in which we are showing very, very strong results in frontline, will portend for a very positive continue adoption of DARZALEX that we see one of the major drivers of the growth of the pharmaceutical group. [end quote]
-
er der noget reelt nyt i den artikel?
-
Den snupper vi nu Stockbull
-
Kan vi følge med nogen steder hvordan det går i USA med tegninger af nye aktier.. jeg forventer megen chat om det i løbet af aftenen eller får vi først news klokken 22
-
@ Von And Hvis det sker er det sandsynligvis først i morgen https://www.nasdaq.com/markets/ipos/activity.aspx?tab=upcoming
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind